Abstract：
UNASSIGNED: Specific biomarkers, such as eosinophilia in peripheral blood or fractional exhaled nitric oxide (FeNO), can guide us in the choice of biologic therapy, allowing a more personalized approach. Although there are multiple evidences in the literature about the role of FeNO as a predictor of response to different biologic treatments, there are no data on the relationship between FeNO changes and clinical response to the four biologic drugs currently in use.
UNASSIGNED: To evaluate and to compare the expression of multiple-flows FeNO parameters in a cohort of patients with severe asthma (SA) before and during the treatment with biologics to evaluate the performance of these biomarkers in predicting the achievement of clinical remission.
UNASSIGNED: We prospectively enrolled 50 patients with severe asthma eligible for biologic therapy. Patients underwent clinical and functional monitoring at baseline (T0) and after 1, 6, and 12 months of treatment (T1, T6, T12), including multiple flows FeNO assessment.
UNASSIGNED: A statistically significant reduction of FeNO50 values and J\'awNO was observed only in benralizumab and dupilumab subgroups. Among biomarkers, the reduction of FeNO 50 values at T1 was associated with a higher probability of achieving clinical remission at T12 (p = 0.003), which was also confirmed by ROC curve analysis (AUC 0.758, p = 0.002; sensitivity 60% and specificity 74% for a reduction of 16 ppb).
UNASSIGNED: These data confirm the potential of this biomarker in predicting clinical response to biologic treatment in patients with severe asthma in order to guide clinical decisions and evaluate a shift to other biologic therapy.
UNASSIGNED: To evaluate and to compare the expression of multiple-flows FeNO parameters in a cohort of patients with severe asthma (SA) before and during the treatment with biologics to evaluate the performance of these biomarkers in predicting the achievement of clinical remission.
UNASSIGNED: We prospectively enrolled 50 patients with severe asthma eligible for biologic therapy. Patients underwent clinical and functional monitoring at baseline (T0) and after 1, 6, and 12 months of treatment (T1, T6, T12), including multiple flows FeNO assessment.
UNASSIGNED: A statistically significant reduction of FeNO50 values and J\'awNO was observed only in benralizumab and dupilumab subgroups. Among biomarkers, the reduction of FeNO 50 values at T1 was associated with a higher probability of achieving clinical remission at T12 (p = 0.003), which was also confirmed by ROC curve analysis (AUC 0.758, p = 0.002; sensitivity 60% and specificity 74% for a reduction of 16 ppb).
UNASSIGNED: These data confirm the potential of this biomarker in predicting clinical response to biologic treatment in patients with severe asthma in order to guide clinical decisions and evaluate a shift to other biologic therapy.
摘要：
背景：特定的生物标志物，如外周血嗜酸性粒细胞增多或部分呼出气一氧化氮（FeNO），可以指导我们选择生物疗法，允许更个性化的方法。尽管文献中关于FeNO作为不同生物治疗反应的预测因子的作用有多种证据,目前尚无关于FeNO变化与目前使用的四种生物药物的临床反应之间关系的数据.
目的：评估和比较一组SA患者在使用生物制剂治疗之前和期间的多流量FeNO参数的表达，以评估这些生物标志物在预测临床缓解方面的表现。
方法：我们前瞻性招募了50名符合生物治疗条件的重度哮喘患者。患者在基线（T0）和治疗后1、6和12个月（T1、T6、T12）接受临床和功能监测，包括多个流量FeNO评估。
结果：仅在贝那利珠单抗和dupilumab亚组中观察到FeNO50值和J'awNO的统计学显著降低。在生物标志物中，T1时FeNO50值的降低与T12时达到临床缓解的概率较高相关(p=0.003),ROC曲线分析也证实了这一点(AUC0.758,p=0.002;灵敏度60%,特异性74%,降低16ppb)。
结论：这些数据证实了该生物标志物在预测重度哮喘患者对生物治疗的临床反应方面的潜力，以指导临床决策并评估向其他生物治疗的转变。
目的：评估和比较一组SA患者在使用生物制剂治疗之前和期间的多流量FeNO参数的表达，以评估这些生物标志物在预测临床缓解方面的表现。
方法：我们前瞻性招募了50名符合生物治疗条件的重度哮喘患者。患者在基线（T0）和治疗后1、6和12个月（T1、T6、T12）接受临床和功能监测，包括多个流量FeNO评估。
结果：仅在贝那利珠单抗和dupilumab亚组中观察到FeNO50值和J'awNO的统计学显著降低。在生物标志物中，T1时FeNO50值的降低与T12时达到临床缓解的概率较高相关(p=0.003),ROC曲线分析也证实了这一点(AUC0.758,p=0.002;灵敏度60%,特异性74%,降低16ppb)。
结论：这些数据证实了该生物标志物在预测重度哮喘患者对生物治疗的临床反应方面的潜力，以指导临床决策并评估向其他生物治疗的转变。
